Financials
Financial year 2025
OCULUX from Bree, company number BE0803897002, closed financial year 2025 with a result of € 0 after tax. For that financial year OCULUX recorded a gross margin of € 597,107 and equity of € 150,000. Compared with financial year 2024, the result moved from € 0 to € 0. Around break-even. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 150,000
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 0
Profit after tax over the fiscal year.
€ 752,923
▼ 16% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 0.
People and assets in 2025
7.5
▲ 1.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 409,081
▼ 19% vs 2024
€ 54,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 18,991
▼ 1% vs 2024
Of which on lease € 6,317.
Debts at end 2025
€ 467,563
▼ 26% vs 2024
€ 178,568 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 52,394
▲ 170% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 888
▼ 56% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 782,119 | € 597,107 | ▼ 24% |
| Equity | € 150,000 | € 150,000 | |
| Total debts | € 1,506,388 | € 1,243,782 | ▼ 17% |
| Cash | € 899,388 | € 752,923 | ▼ 16% |
| Land & buildings | - | € 22,432 | |
| Bank debt | € 634,606 | € 467,563 | ▼ 26% |
| Balance sheet total | € 1,656,388 | € 1,393,782 | ▼ 16% |
| Employees (FTE) | 6.1 | 7.5 | ▲ 1.4 |
Key figures of OCULUX, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OCULUX?
What happened at OCULUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 0. Source: NBB ↗
- New establishment in Bree. KBO
- Start of the company according to the CBE. KBO
- Dr. Leen Clijsters BV became a director. NBB
- ASPR BV became a director. NBB
In short
From € 0 profit in 2024 to € 0 profit in 2025.
Paid € 3,446 in corporate taxes since 2024.
On average € 79,600 of value added per employee in 2025.
Management
The stake of Dr. Leen Clijsters, ASPR comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
OCULUXBehind OCULUX are Dr. Leen Clijsters BV and ASPR BV . The shares are held by Dr. Leen Clijsters (50%) and ASPR (50%).
Directors
According to the 2025 annual accounts
Director · represented by Leen Clijsters
since 2023
Director · represented by Sofie Le Piane
since 2023
Shareholders
50%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Witte Torenwal 9 box A1
3960 Bree
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.897.002
- VAT number
- BE 0803.897.002
- Registered office
- Witte Torenwal 9 bus A1, 3960 Bree
- Names & denominations
- OCULUX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 12 July 2023
- Peppol
- Active · Active since 20 Feb 2026
- Activities · NACE
Activiteiten van medisch specialisten